Proxy Votes Now

Home › Funds › Brighthouse › T. Rowe Price Mid Cap Growth Portfolio

T. Rowe Price Mid Cap Growth Portfolio proxy voting record 2025-2026

Fund family: Brighthouse · Filed by Brighthouse Funds Trust I (CIK 1126087) · SEC series S000011103

“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 1,161 with, 22 against, 0 abstentions (not counted as with management); 2 items carried no recommendation. Shareholder proposals: 8 FOR, 12 AGAINST, 0 abstained, by the filing’s own vote-source field.

Compared with Brighthouse as a whole

The same two figures as Brighthouse’s manager page (247,741 ballot items across 83 funds and accounts), counted the same way for this fund.

2025-2026This fundItemsBrighthouseItems
Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters)93.4%1,11876.3%204,500
Backed environmental and social shareholder proposals at US companiesn/a212.8%1,182

Where this fund voted differently from most Brighthouse funds

Each ballot item this fund voted is set against the votes of the other Brighthouse funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.

Voted differently from most Brighthouse funds on 65 items (6.8% of the 961 items where a comparison was possible).

The most lopsided family majorities first, then the largest companies, then shareholder proposals.
CompanyMeetingItemThis fundMost Brighthouse fundsMgmtResult
Microchip Technology Incorporated2025-08-19Proposal to approve, on an advisory (non-binding) basis, the compensation of our named executives.ForAGAINST or ABSTAIN — 8 of 8 Brighthouse fundsForNot approved, 45.6% support
Molina Healthcare, Inc.2026-05-06To consider and approve an amendment to the Company's 2025 Equity Incentive Plan to increase the number of shares available for issuance under such plan.ForAGAINST or ABSTAIN — 7 of 7 Brighthouse fundsForPassed (calculated), 73.5% support
Natera, Inc.2026-06-11To elect three directors named in the proxy statement accompanying this notice to serve as Class II directors until the annual meeting of stockholders held in 2029 and until their successors are duly elected and qualified, and to elect one director named in the proxy statement accompanying this notiWithholdFOR — 4 of 4 Brighthouse fundsAgainstPassed (calculated), 98.3% support
Insulet Corporation2026-05-20Election of Directors: Luciana BorioWithholdFOR — 4 of 4 Brighthouse fundsAgainstPassed (calculated), 93.5% support
Insulet Corporation2026-05-20Election of Directors: Michael R. MinogueWithholdFOR — 4 of 4 Brighthouse fundsAgainstPassed (calculated), 91.1% support
Insulet Corporation2026-05-20Election of Directors: Timothy C. StonesiferWithholdFOR — 4 of 4 Brighthouse fundsAgainstPassed (calculated), 95.4% support
Dutch Bros Inc.2026-05-13Election of Directors: Todd PenegorAgainstFOR — 4 of 4 Brighthouse fundsAgainstElected, 91.7% support
Veeva Systems Inc.2026-06-17To elect the following to serve as directors until the annual meeting to be held in 2027 or until their successors are duly elected and qualified: Gordon RitterForABSTAIN or AGAINST — 7 of 9 Brighthouse fundsForElected, 73.6% support
Veeva Systems Inc.2026-06-17To elect the following to serve as directors until the annual meeting to be held in 2027 or until their successors are duly elected and qualified: Mark CargesForABSTAIN or AGAINST — 7 of 9 Brighthouse fundsForElected, 80.0% support
Veeva Systems Inc.2026-06-17To elect the following to serve as directors until the annual meeting to be held in 2027 or until their successors are duly elected and qualified: Matthew J. WallachForAGAINST — 3 of 3 Brighthouse fundsForElected, 63.7% support
MongoDB, Inc.2026-06-30Election of three Class III directors, each to serve until our Annual Meeting of Stockholders in 2029: Dwight MerrimanForWITHHOLD — 3 of 3 Brighthouse fundsForElected, 80.4% support
APi Group Corporation2026-05-15To elect nine directors for a one-year term expiring at the 2027 Annual Meeting of Shareholders: Cyrus D. WalkerForAGAINST — 5 of 6 Brighthouse fundsForPassed (calculated), 81.1% support
Assurant, Inc.2026-05-21Shareholder Stockholder proposal regarding action by written consent.AgainstFOR — 5 of 6 Brighthouse fundsForNot approved, 29.2% support
Manhattan Associates, Inc.2026-05-14Election of Directors: Eddie CapelAgainstFOR — 3 of 3 Brighthouse fundsAgainstElected, 85.6% support
Manhattan Associates, Inc.2026-05-14Election of Directors: Linda T. HollembaekAgainstFOR — 3 of 3 Brighthouse fundsAgainstElected, 75.4% support
The New York Times Company2026-04-22Election of Directors: Class A Nominees: Brian P. McAndrewsWithholdFOR — 3 of 3 Brighthouse fundsAgainstPassed (calculated), 81.7% support
The New York Times Company2026-04-22Election of Directors: Class A Nominees: John W. Rogers, Jr.WithholdFOR — 3 of 3 Brighthouse fundsAgainstPassed (calculated), 91.2% support
Planet Fitness, Inc.2026-05-05Election of the four director nominees named in the proxy statement as set forth below: Stephen Spinelli, Jr.ForWITHHOLD — 3 of 3 Brighthouse fundsForElected, 73.5% support
Viking Holdings Ltd2026-05-13Elect Director Torstein HagenForAGAINST — 3 of 3 Brighthouse fundsFor—
Viking Holdings Ltd2026-05-13Elect Torstein Hagen as Board ChairmanForAGAINST — 3 of 3 Brighthouse fundsFor—
Yum! Brands, Inc.2026-05-14Shareholder Shareholder Proposal to Reduce the Percentage of Shares Required to Call a Special Meeting.AgainstFOR — 8 of 13 Brighthouse fundsForNot approved, 37.7% support
Cboe Global Markets, Inc.2026-05-14Shareholder Stockholder proposal regarding shareholder right to act by written consent.AgainstFOR — 6 of 9 Brighthouse fundsFor—
Biogen Inc.2026-06-09Election of Directors. To elect the 10 nominees identified in the accompanying Proxy Statement to our Board of Directors to serve for a one-year term extending until our 2027 annual meeting of stockholders and their successors are duly elected and qualified: Maria C. FreireForABSTAIN or AGAINST — 7 of 11 Brighthouse fundsForPassed (calculated), 84.6% support
Biogen Inc.2026-06-09Say on Pay - To hold an advisory vote on executive compensation.ForABSTAIN or AGAINST — 7 of 11 Brighthouse fundsForApproved, 93.9% support
Biogen Inc.2026-06-09To ratify the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for fiscal year ending December 31, 2026.ForABSTAIN or AGAINST — 7 of 11 Brighthouse fundsForApproved, 94.9% support
Show all 65
Items 26 to 65.
CompanyMeetingItemThis fundMost Brighthouse fundsMgmtResult
Natera, Inc.2026-06-11To approve an amendment to Natera's 2015 Equity Incentive Plan, as amended and restated.ForABSTAIN or AGAINST — 9 of 16 Brighthouse fundsForPassed (calculated), 78.1% support
StandardAero, Inc.2026-06-253 wordings Election of Class II Directors to serve until the 2029 Annual Meeting of Stockholder, and until their respective successors shall have been duly elected and qualified: Douglas V. BrandelyForWITHHOLD — 5 of 8 Brighthouse fundsForElected, 85.0% support
Cytokinetics, Incorporated2026-05-27Election of Class I Directors for terms expiring in 2029: Wendell Wierenga, Ph.D.WithholdFOR — 5 of 8 Brighthouse fundsAgainstPassed (calculated), 79.2% support
CG Oncology, Inc.2026-06-04To elect the Board's two nominees for Class II director named as nominees to hold office until the 2029 Annual Meeting of Stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Victor Tong, Jr.ForWITHHOLD — 5 of 8 Brighthouse fundsForElected, 92.3% support
Hologic, Inc.2026-02-05A proposal to approve any adjournment of the special meeting for the purpose of soliciting additional proxies if there are insufficient votes at the special meeting to adopt the merger agreement.AgainstFOR — 6 of 10 Brighthouse fundsAgainst—
Atlassian Corporation2025-12-02Election of Directors: Michael Cannon-BrookesForABSTAIN or AGAINST — 3 of 4 Brighthouse fundsForPassed (calculated), 96.9% support
Atlassian Corporation2025-12-02Election of Directors: Scott FarquharForABSTAIN or AGAINST — 3 of 4 Brighthouse fundsForPassed (calculated), 96.9% support
Markel Group Inc.2026-05-20Shareholder Shareholder proposal to give shareholders an ability to call for a special shareholder meeting.AgainstFOR — 3 of 4 Brighthouse fundsForFailed (calculated), 37.3% support
Kymera Therapeutics, Inc.2026-06-24To elect four class III directors to our Board of Directors, each to serve until the 2029 Annual Meeting of Shareholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Bruce Booth, D.Phil.ForWITHHOLD — 3 of 4 Brighthouse fundsForPassed (calculated), 93.0% support
Kymera Therapeutics, Inc.2026-06-24To elect four class III directors to our Board of Directors, each to serve until the 2029 Annual Meeting of Shareholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Elena Ridloff, CFAForWITHHOLD — 3 of 4 Brighthouse fundsForPassed (calculated), 93.6% support
Kymera Therapeutics, Inc.2026-06-24To elect four class III directors to our Board of Directors, each to serve until the 2029 Annual Meeting of Shareholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: John Maraganore, Ph.D.ForWITHHOLD — 3 of 4 Brighthouse fundsForPassed (calculated), 93.7% support
Kymera Therapeutics, Inc.2026-06-24To elect four class III directors to our Board of Directors, each to serve until the 2029 Annual Meeting of Shareholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Nello Mainolfi, Ph.D.ForWITHHOLD — 3 of 4 Brighthouse fundsForPassed (calculated), 94.9% support
Vaxcyte, Inc.2026-06-152 wordings Election of Class III Directors Nominees would serve until the 2029 Annual Meeting of Stockholders and until their successors have been duly elected and qualified, or, if sooner, until the director's death, resignation or removal: Olivier Brandicourt, M.D.ForWITHHOLD — 3 of 4 Brighthouse fundsForPassed (calculated), 87.5% support
Aurora Innovation, Inc.2026-05-21Election of Directors: Gloria BoylandForWITHHOLD — 3 of 4 Brighthouse fundsForElected, 97.3% support
Nuvalent, Inc.2026-06-16Election of the following nominees as Class II directors: Michael L. Meyers, M.D., Ph.D.ForWITHHOLD — 3 of 4 Brighthouse fundsForElected, 81.5% support
Biogen Inc.2026-06-098 wordings Election of Directors. To elect the 10 nominees identified in the accompanying Proxy Statement to our Board of Directors to serve for a one-year term extending until our 2027 annual meeting of stockholders and their successors are duly elected and qualified: William A. HawkinsForABSTAIN — 6 of 11 Brighthouse fundsForPassed (calculated), 83.8% support
Cheniere Energy, Inc.2026-05-14Election of Directors: Patricia K. CollawnForABSTAIN or AGAINST — 5 of 9 Brighthouse fundsForElected, 94.2% support
Veeva Systems Inc.2026-06-17To elect the following to serve as directors until the annual meeting to be held in 2027 or until their successors are duly elected and qualified: Mary Lynne HedleyForABSTAIN or AGAINST — 5 of 9 Brighthouse fundsForElected, 86.6% support
Alnylam Pharmaceuticals, Inc.2026-05-20To ratify the appointment of PricewaterhouseCoopers LLP, an independent registered public accounting firm, as Alnylam's independent auditors for the fiscal year ending December 31, 2026.ForABSTAIN or AGAINST — 5 of 9 Brighthouse fundsForApproved, 95.3% support
ITT Inc.2026-05-21Approval of a non-binding advisory vote on executive compensationForABSTAIN — 4 of 7 Brighthouse fundsForApproved, 96.8% support
ITT Inc.2026-05-21Ratification of the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for the 2026 fiscal yearForABSTAIN — 4 of 7 Brighthouse fundsForApproved, 97.3% support
Zscaler, Inc.2026-01-12To approve on a non-binding, advisory basis, the frequency of future stockholder advisory votes on the compensation of our named executive officers.ForABSTAIN — 3 of 5 Brighthouse fundsFor—
Ball Corporation2026-04-29Election of Directors: Todd A. PenegorAgainstFOR — 3 of 5 Brighthouse fundsAgainstPassed (calculated), 60.3% support
Service Corporation International2026-05-06To approve the 2026 Equity Incentive Plan.ForAGAINST — 3 of 5 Brighthouse fundsForApproved, 78.1% support
Avantor, Inc.2026-05-07Election of Directors: Dame Louise MakinForABSTAIN or AGAINST — 3 of 5 Brighthouse fundsForPassed (calculated), 95.7% support
Avantor, Inc.2026-05-07Election of Directors: Gregory LucierForABSTAIN or AGAINST — 3 of 5 Brighthouse fundsForPassed (calculated), 97.6% support
Avantor, Inc.2026-05-07Election of Directors: Gregory SummeForABSTAIN or AGAINST — 3 of 5 Brighthouse fundsForPassed (calculated), 87.0% support
Avantor, Inc.2026-05-07Election of Directors: Joseph MassaroForABSTAIN or AGAINST — 3 of 5 Brighthouse fundsForPassed (calculated), 95.3% support
Wyndham Hotels & Resorts, Inc.2026-05-14Shareholder To vote on a stockholder proposal, if properly presented at the meeting, regarding stockholder ability to act by written consent.AgainstFOR — 3 of 5 Brighthouse fundsForPassed (calculated), 62.9% support
Revolution Medicines, Inc.2026-06-18To elect two Class III directors to hold office until the 2029 Annual Meeting of Stockholders or until his successor is elected: Alexis BorisyForWITHHOLD — 2 of 3 Brighthouse fundsForPassed (calculated), 79.1% support
DraftKings Inc.2026-05-12To conduct a non-binding advisory vote on executive compensation.ForABSTAIN or AGAINST — 2 of 3 Brighthouse fundsForPassed (calculated), 97.2% support
Ralliant Corporation2026-06-05Advisory vote on the frequency of future advisory votes to approve Ralliant's named executive officer compensation.ForABSTAIN — 2 of 3 Brighthouse fundsFor—
Ionis Pharmaceuticals, Inc.2026-06-04Election of Directors: Spencer R. BerthelsenAgainstFOR — 2 of 3 Brighthouse fundsAgainstPassed (calculated), 85.2% support
CRISPR Therapeutics AG2026-06-04Approval of the CRISPR Therapeutics AG 2026 Stock Option and Incentive Plan.ForAGAINST — 2 of 3 Brighthouse fundsForApproved, 88.1% support
CRISPR Therapeutics AG2026-06-04Binding vote on maximum equity for members of the Board of Directors from the 2026 Annual General Meeting to the 2027 annual general meeting of shareholders.ForAGAINST — 2 of 3 Brighthouse fundsFor—
CRISPR Therapeutics AG2026-06-04Binding vote on maximum equity for members of the Executive Committee from the 2026 Annual General Meeting to the 2027 annual general meeting of shareholders.ForAGAINST — 2 of 3 Brighthouse fundsFor—
CRISPR Therapeutics AG2026-06-04Binding vote on maximum non-performance-related compensation for members of the Executive Committee from July 1, 2026 to June 30, 2027.ForAGAINST — 2 of 3 Brighthouse fundsFor—
CRISPR Therapeutics AG2026-06-04Binding vote on maximum variable compensation for members of the Executive Committee for the current year ending December 31, 2026.ForAGAINST — 2 of 3 Brighthouse fundsFor—
CRISPR Therapeutics AG2026-06-04Non-binding advisory vote on the 2025 Compensation Report.ForAGAINST — 2 of 3 Brighthouse fundsFor—
CRISPR Therapeutics AG2026-06-04Non-binding advisory vote on the compensation paid to the Company's named executive officers under U.S. securities law requirements.ForAGAINST — 2 of 3 Brighthouse fundsForApproved, 69.4% support

Download all 65 differences (CSV)

Votes against management by sector

The same votes as “with management” above, by the sector of the company voted on. 92.4% of this fund’s 1,183 such votes could be given a sector; the other 90 (7.6%) are at companies without one and are not in the table.

SectorVotesAgainst managementShare
Consumer Discretionary33892.7%
Health Care21910.5%
Industrials17610.6%
Technology17121.2%
Finance12964.7%
Miscellaneous2600.0%
Utilities2114.8%
Energy1300.0%

What it voted on

Ballot items by the category the filing put first; “against management” as above.
Proposal typeItemsAgainst management
Director Elections8430
Audit-related1100
Say-on-Pay1080
Corporate Governance5719
Compensation360
Capital Structure180
Shareholder Rights and Defenses81
Extraordinary Transactions30
Environment or Climate11
Other Social Issues11

Its largest holdings’ meetings

Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.

CompanyMeetingEst. positionItemsAgainst mgmt
Hilton Worldwide Holdings Inc.May 14, 2026$35M130
Agilent Technologies, Inc.March 18, 2026$30M70
Mettler-Toledo International Inc.May 7, 2026$26M110
PTC Inc.February 11, 2026$26M100
Lattice Semiconductor CorporationMay 1, 2026$25M100
Assurant, Inc.May 21, 2026$24M141
Veeva Systems Inc.June 17, 2026$23M100
Yum! Brands, Inc.May 14, 2026$21M141

Notable votes against management

MeetingCompanyProposalFundMgmt
May 21, 2026Assurant, Inc.Stockholder proposal regarding action by written consent. Shareholder proposalAgainstFor
May 14, 2026Yum! Brands, Inc.Shareholder Proposal to Reduce the Percentage of Shares Required to Call a Special Meeting. Shareholder proposalAgainstFor
March 19, 2026Keysight Technologies, Inc.Consider, on a non-binding advisory basis, a Stockholder Proposal: Shareholder Ability to Call for a Special Shareholder Meeting Shareholder proposalForAgainst
June 16, 2026Dollar Tree, Inc.Shareholder proposal requesting a shareholder right to act by written consent. Shareholder proposalAgainstFor
September 3, 2025Casey's General Stores, Inc.Shareholder proposal regarding Scope 3 greenhouse gas reduction targets. Shareholder proposalAgainstFor
May 4, 2026West Pharmaceutical Services, Inc.Shareholder proposal regarding an independent Board Chair policy. Shareholder proposalForAgainst
May 14, 2026Cboe Global Markets, Inc.Stockholder proposal regarding shareholder right to act by written consent. Shareholder proposalAgainstFor
April 21, 2026Domino's Pizza, Inc.Shareholder proposal regarding departure of directors who fail to obtain a majority vote. Shareholder proposalAgainstFor
April 21, 2026Domino's Pizza, Inc.Shareholder proposal regarding an independent board chair requirement. Shareholder proposalForAgainst
April 30, 2026Avery Dennison CorporationVote on stockholder proposal for an independent Board Chairman, if properly presented during the meeting. Shareholder proposalForAgainst
January 12, 2026Zscaler, Inc.To vote on a non-binding stockholder proposal requesting the declassification of our board of directors. Shareholder proposalForAgainst
May 20, 2026Markel Group Inc.Shareholder proposal for a report on the Company's strategies and action plans to mitigate material environmental risks. Shareholder proposalAgainstFor

Search this fund’s votes by company

1,185 ballot items at 111 meetings in 2025-2026. Download all votes (CSV)

Recent notable votes

Recent votes against management’s recommendation at large companies.

About this fund’s record

In the 2025-2026 proxy season, T. Rowe Price Mid Cap Growth Portfolio voted at 111 shareholder meetings of 109 companies, on 1,185 ballot items in all. Where management made a recommendation, the fund followed it on 98.1% of the items and voted against it 22 times. Its most frequent area of disagreement was corporate governance (19 of its votes against management). It voted on 20 shareholder proposals. It voted FOR the board's own proposals more often than Brighthouse's funds as a whole (93.4% against 76.3%). It voted differently from most Brighthouse funds on 65 items.

About this page

Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of Brighthouse’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.